Engineered immune cells take aim at tough blood cancers
NCT ID NCT07345780
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new treatment using the body's own immune cells, called CAR-T cells, to fight certain blood cancers (like T-cell leukemia/lymphoma) that have returned or not responded to standard therapy. The study will enroll about 20 to 28 adults aged 18-85. The main goals are to check if the treatment is safe and to see how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••